A Study to Investigate the Biological Effects of AZD9833 in Women with ER-positive, HER2 Negative Primary Breast Cancer

Trial Identifier: D8530C00003
Sponsor: AstraZeneca
NCTID:: NCT04588298
Start Date: November 2020
Primary Completion Date: June 2023
Study Completion Date: June 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
GB Bournemouth, GB, BH7 7DW
GB Derby, GB, DE22 3NE
GB Leicester, GB, LE1 5WW
GB Liverpool, GB, L7 8XP
GB London, GB, W12 0HS
GB Manchester, GB, M23 9LT
GB Poole, GB, BH15 2JB
GB Sutton In Ashfield, GB, NG17 4JL
GE Batumi, GE, 6000
GE Tbilisi, GE, 0179
GE Tbilisi, GE, '0112
GE Tbilisi, GE, 0159
GE Tbilisi, GE, 0186
GE Tbilisi, GE, '0186
MX Aguascalientes, MX, 20230
MX D.F, MX, 14000
MX México, MX, 06726
MX Mexico City, MX, '14080
MX Tlalpan, MX, 14050